<DOC>
	<DOC>NCT00002042</DOC>
	<brief_summary>To determine the safety and efficacy of r-HuEPO administration to patients with AIDS or advanced AIDS related complex (ARC) and anemia secondary to their disease.</brief_summary>
	<brief_title>A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Exclusion Criteria Coexisting Condition: Patients with the following are excluded: History of any primary hematologic disease. HIV disease related dementia. Uncontrolled hypertension (diastolic blood pressure &gt; 100 mmHg). Presence of concomitant iron deficiency. Anemia attributable to factors other than HIV disease or zidovudine (AZT) therapy. Acute opportunistic infection. History of seizures. Clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying HIV disease. Concurrent Medication: Excluded: Zidovudine (AZT) therapy during the doubleblind phase of study. Patients with the following are excluded: History of any primary hematologic disease. Clinically significant disease / dysfunction of the pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal, or genitourinary systems not attributable to underlying HIV disease. HIV disease related dementia. Uncontrolled hypertension (diastolic blood pressure &gt; 100 mmHg). Presence of concomitant iron deficiency. Prior Medication: Excluded within 30 days of study entry: Experimental drug or experimental device. Cytotoxic chemotherapy. Excluded within 2 months of study entry: Androgen therapy. Zidovudine (AZT) therapy and during the doubleblind phase. Clinical diagnosis with AIDS or AIDS related complex (ARC) and related anemia. Clinical diagnosis of AIDS or ARC. Clinically stable for 1 month preceding study entry. Patients should preferably be transfusion dependent. Substance abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 1989</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anemia</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>